The DOI matches its Crossref record; its reference list is not available; 24 of the 129 sources its claims cite were checked for support.
Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment
Open accessAbstract
Depression is a leading cause of disability worldwide and improving its treatment is a core research priority for future programmes. A change in the view of psychological and biological processes, from seeing them as separate to complementing one another, has introduced new perspectives on pathological mechanisms of depression and treatment mode of action. This review presents a theoretical model that incorporated this novel approach, the cognitive neuropsychological hypothesis of antidepressant action. This model proposes that antidepressant treatments decrease the negative bias in the processing of emotionally salient information early in the course of antidepressant treatment, which leads to the clinically significant mood improvement later in treatment. The paper discusses the role of negative affective biases in the development of depression and response to antidepressant treatments. It also discusses whether the model can be applied to other antidepressant interventions and its potential translational value, including treatment choice, prediction of response and drug development.
Overview
CoChat Summary
TL;DR
The paper reviews the cognitive neuropsychological hypothesis of antidepressant action, which proposes that antidepressants first reduce negative bias in emotional processing and that this early shift, combined with social-environment interactions, later produces mood improvement. It surveys behavioral, neuroimaging, animal, and treatment studies supporting the model and discusses its translational potential and unresolved gaps.
Key findings
- The model addresses the delayed clinical effect of conventional antidepressants: biological effects occur within hours, but symptomatic improvement is rarely seen before 1 week, with clear and sustained effects often not evident until 4–6 weeks.
- Short-term antidepressant treatment in healthy volunteers and depressed patients shifts emotional processing at behavioral and neural levels; for example, 7 days of escitalopram differentiated 6-week responders from non-responders across regions including left amygdala, insula, anterior and posterior cingulate, supramarginal gyri, and thalamus, while placebo-controlled fMRI showed normalization of amygdala responsiveness without mood differences.
- Early emotional-processing measures predicted later response: Browning et al. (2019) reported 77% accuracy in a training sample of 74 primary care patients and 60% in an independent sample of 239; Shiroma et al. (2014) found that 7-day citalopram-related happy-face recognition predicted remission at 56 days in 27 older depressed adults only when perceived social support was adequate.
- Translational implications include treatment personalization and drug development; memantine and aprepitant failed to affect emotional processing and lacked antidepressant efficacy, while rimonabant reduced positive bias and was associated with depressive symptoms and suicidal ideation.
Methods
- Narrative review and theoretical synthesis of the cognitive neuropsychological hypothesis; no new primary data are reported.
- Synthesizes human behavioral and fMRI/PET studies, healthy-volunteer and depressed-patient samples, animal models, and trials or studies of pharmacological, ECT, TMS/tDCS, DBS, CBT, and cognitive bias modification interventions.
- Main analysis is qualitative integration of cited evidence, including selected quantitative results from cited studies such as prediction accuracies and sample sizes.
Limitations
- Stated in the paper: the early emotional-processing shift is not yet ready for wider clinical use; more work is needed to improve prediction accuracy and differentiate drug classes or individual medications; the social-interaction component requires further testing; the timeline and which emotion’s processing modification is crucial remain unclear; ketamine/glutamatergic applications need validation; and early emotional-processing shift during CBT has not yet been explored in depression.
- Evident from the text: as a narrative review, conclusions depend on cited studies with heterogeneous designs, doses, samples, and measures, and no systematic search or meta-analytic synthesis is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
20 Valid · 2 Not valid · 64 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“symptomatic improvement is rarely seen before 1 week”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The cognitive neuropsychological hypothesis of antidepressant action
What the sources say
- Partly supportedcites Taylor 2007 sourceExperimental — accuracy not yet measured
Taylor et al. (2006) support only the 'rarely seen' element, and only for individual trials: the COMMENT states that 'statistically significant early differences are infrequently seen in individual RCTs powered to demonstrate treatment effects at a trial end point,' and the introduction notes that many trials report no significant SSRI-over-placebo benefit until after several weeks. What the source does not support is the claim as a statement about the pre-week-1 period: its pooled analyses (Abstract Data Synthesis; RESULTS, Rating scale scores) begin at week 1 and conclude that drug-attributable symptomatic improvement is present by the end of the first week, with the greatest incremental effect in week 1 and a model that 'apparently exclud[es] the possibility that treatment response from antidepressant drugs is subject to a period of delay.' No passage in our copy addresses symptom change within the first 7 days, so the citing sentence both overstates the source's scepticism (which is about statistical power, not absence of early effect) and inverts its thesis, which is that the conventional delay doctrine (2-3 weeks) is wrong. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the molecular, cellular and chemical effects occur very quickly after a drug gets administered, within the course of hours”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The cognitive neuropsychological hypothesis of antidepressant action
What the sources say
- Partly supportedcites Taylor 2007 sourceExperimental — accuracy not yet measured
The COMMENT section states that 'Inhibition of serotonin transporters occurs rapidly in vitro and in vivo,' which supports the claim that a molecular/biochemical effect of SSRI administration is immediate. However, our copy never quantifies this as 'within hours,' and it does not extend rapidity to cellular effects: the same passage attributes adaptive neurobiologic changes (5-HT1A receptor desensitization, BDNF expression, citing refs 57,58) to the time course that is invoked to explain delay, and places the earliest documented downstream neurochemical and psychological effects 'in the first week of use.' The paper's own positive finding is clinical improvement detectable by the end of week 1 (Abstract Conclusions; Results, Rating Scale Scores), not effects within hours, so the 'within the course of hours' and 'cellular' components of the claim are unsupported. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“take longer to name the colour of negative emotional words in the emotional Stroop task”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The point of focus for the CNP model: negative bias in processing of emotionally salient information in depression
What the sources say
- Supportedcites Roiser et al. 2012 source
The Emotional Attention section directly states that depressed patients tend to take longer to name the color of negative emotional words in emotional Stroop tasks. The claim preserves the paper’s qualifier, “tend to.” (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“people with depression are more likely to perceive and categorize ambiguous facial expressions as negative in the Facial Emotions Recognition Test (FERT)”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The point of focus for the CNP model: negative bias in processing of emotionally salient information in depression
What the sources say
- Partly supportedcites Roiser et al. 2012 sourceExperimental — accuracy not yet measured
The Emotional Perception section reports a bias toward negative facial-emotion perception in depression, including a greater tendency to label faces as sad. It does not identify those faces as ambiguous or attribute the finding specifically to the Facial Emotions Recognition Test (FERT); searches for those terms found no supporting passage. (LLM, conf=0.85)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Medications, on the other hand, have been suggested to act on the structures directly involved in the negative bias formation, primarily on the extended limbic system (‘bottom-up’ effect)”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The point of focus for the CNP model: negative bias in processing of emotionally salient information in depression
What the sources say
- Partly supportedcites Roiser et al. 2012 sourceExperimental — accuracy not yet measured
In ‘The Cognitive Neuropsychological Model of Depression’ (page not provided), the paper proposes that antidepressants attenuate ‘bottom-up’ affective biases. ‘The Influence of Cognitive Control’ identifies enhanced responses to negative information in the extended limbic system. The paper does not establish that medications act primarily on that system; its medication-effects section also reports changes in prefrontal responses. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
69 more claims · 11 with their cited sources checked
Create a free account to see all 119 claims and to verify the 105 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Amygdala reac vity to nega ve informa on is a marker of nega ve affec ve processes in depression that is reduced by an depressant medica on.”
From Amygdala Reactivity, Antidepressant Discontinuation, and Relapse (2024) · cites this paper as [20]
In the citing paper
“This cognitive neuropsychological model of antidepressant action suggests that acute effects of antidepressants on emotional processing promote more positive social interactions [36, 103].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [36]
In the citing paper
“For instance, serotonergic antidepressants result in acute changes in emotion processing within a week (and even after one dose) in humans, such that individuals are less likely to interpret ambiguous faces as negative and demonstrate increased attentional and memory bias for positive versus negative stimuli (reviewed by Godlewska and Harmer [36]).”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The point of focus for the CNP model: negative bias in processing of emotionally salient information in depression
“activity in the extended limbic system including the amygdala, pregenual anterior cingulate cortex (pgACC), and hippocampus, differed between depressed and healthy individuals, suggesting their role in the development and maintenance of emotional processing bias (e.g. Mayberg 2003) (Fig. 2).”
§ Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment > The point of focus for the CNP model: negative bias in processing of emotionally salient information in depression
“Figure: Fig. 2 The hypothetical place of rapid acting ADs within the cognitive neuropsychological model of antidepressant action. Rapid-acting ADs, such as ketamine, were hypothesised to reduce or abolish memory for already existing negative associations.”
Citations
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 119 · Cited by 123
Research works printed but not linked: 1
- Robinson ES, Roiser JP (2016) Affective biases in humans and animals. Curr Top Behav Neurosci 28:263–286 · DOI · Paper page
Metadata
- Authors
- Godlewska, B. R., & Harmer, C. J.
- Affiliations
- Warneford Hospital (GB)
- Oxford Health NHS Foundation Trust (GB)
- Corresponding author
- Godlewska, Beata R.
- Venue
- Psychopharmacology
- Published
- 2020-01-15
- Volume
- 238
- Issue
- 5
- Pages
- 1265-1278
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC8062380
- OpenAlex
- W2999837842
- Cited by
- 123
- References
- 119
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 20 · 2023: 21 · 2022: 26 · 2021: 16 · 2020: 6
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oxford
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- depression, antidepressant action, mood improvement, treatment response prediction, antidepressant drug development, treatment selection, translational psychiatry
- MeSH terms
- Affect, Antidepressive Agents, Cognition, Depression, Emotions, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. https://app.cochat.ai/papers/10.1007/s00213-019-05448-0
- The paper
- Godlewska, B. R., & Harmer, C. J. (2021). Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. Psychopharmacology. https://doi.org/10.1007/s00213-019-05448-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.